Average Sales Price Resource Center
Effective January 1, 2005, Medicare implemented a new Average Sale Price-based methodology for certain Medicare Part B-covered drugs administered in physician offices as well IVIG and respiratory medications. NHIA members have expressed serious concerns about how ASP will be interpreted by non-Medicare payers and whether these payers understand the impact ASP pricing would have on access to home infusion therapies. Members have also sought contractual strategies to reduce the risk that payers will implement sudden and arbitrary pricing changes.
Important note: Medicare reimbursement for infusion drugs furnished in the home through an item of DME (except home IVIG) continues to be at 95% of AWP. Read more below about recent Medicare reimbursement changes.
The ASP Resource Center is designed to provide a clearinghouse for tools and member resources addressing Medicare and non-Medicare issues related to ASP.